Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1990-11-01
1993-09-28
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 289, A61K 3170, C07H 1923
Patent
active
052486729
ABSTRACT:
This invention relates to novel polysubstituted benzimidazole nucleosides and compositions and their use in the treatment of viral infections, particulary those caused by human cytomegalovirus and herpes simplex virus. Such substituted compounds exhibit antiviral properties superior to their parent compounds and low leve
REFERENCES:
patent: 2935508 (1960-05-01), Shunk et al.
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 3311628 (1967-03-01), Partyka
patent: 3631036 (1971-12-01), Kim et al.
patent: 3817982 (1974-06-01), Verheyden et al.
patent: 3867386 (1975-02-01), Kim et al.
patent: 3962211 (1976-06-01), Townsend et al.
patent: 4199574 (1980-04-01), Schaeffer
patent: 4229453 (1980-10-01), Roth et al.
patent: 4596798 (1986-06-01), Shipman, Jr. et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 4927830 (1990-05-01), Townsend et al.
patent: 4968686 (1990-11-01), Townsend et al.
Tamm, I., "Inhibitor of Influenza and Mumps Virus Multiplication by 4,5,6,-(or 5,6,7,-) Trichloro-1- -D-Ribofuranosyl-benzimidazole," Science, 120:847-848 (1954).
Townsend, L. B. et al., "Benzimidazole Nucleosides, Nucleotides, and Related Derivatives," Chemical Reviews, 70:389-438 (1970).
Zou, R., "Synthesis and Antiviral Activity of 1- -D-Ribofuranosyl-2,4,6-Tri-Chlorobenzimidazole," American Chemical Society, Apr. 1990.
Devivar, R. V. et al., "The Formation of an Unusual Product During Studies on the Diazotization of Certain 2-Aminobenzimidazoles," American Chemical Society, Apr. 1990.
Hayflick, L. "Screening Tissue Cultures for Mycoplasma Infections," in P. F. Kruse, Jr. and M. K. Patterson, Jr. (ed), Tissue culture:methods and applications Academic Press Inc., New York, 1973, pp. 722-728.
Drach et al., "Comparison of Activity of Tubercidin Analogs Against Herpesviruses," 28th ICAAC, Los Angeles, Calif., Oct. 1988.
Saluja, S. et al., "Synthesis and Antiviral Activity of Certain 2-Substituted 4,5,6,7-Tetrachlorobenzimidazole Acyclic Nucleosides," American Chemical Society, Apr. 1990.
Nassiri et al., "Kinetic Assessment by Flow Cytometry of the Effect of Two New Antiviral Drugs on the Cell Cycle," 3rd Annual Meeting Clinical Application of Cytometry, Sep. 1988.
Duffy, T., et al., "Pyrrolo[2,3-d] pyrimidines, Synthesis from 4-Pyrimidyhydrazones, a 2-Bis(methylthio)methyleneaminopyrrolo-3-carbonitrile, and a Pyrrolo[2,3-d][1,3]thiazine-2(1H)-thione", J. Chem. Soc., 16:1921-1929 (1974).
Sigma Chemical Co. Catalog, St. Louis, Mo., 1984, p. 898.
Saxena, N. K., et al., "Synthesis and Antiviral Activity of Certain 4-Substituted and 2,4-Disubstituted 7-[(2-Hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines", J. Med. Chem., 31:1501-1506 (1988).
Robins, M. J., et al., "Nucleic acid related compounds.24.Transformation of tubercidin 2',3'-O-orthoscetape into halo, deoxy, epoxide, and unsaturated sugar nucleosides.sup.1,2 " 55:1251-1259 (1977).
Drach, J. C., et al., "Tritiated Thymidine Incorporation Does Not Measure DNA Synthesis in Ribavirin-Treated Human Cells", Science, 212:549-551 (1981).
Shipman, C., Jr., et al., "Evaluation of 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic Acid (HEPES) as a Tissue Culture Buffer", Proc. Soc. Exp. Biol. Med. 120:305-310 (1969).
Gupta, P. K., et al., "Synthesis, Cytotoxicity, and Antiviral Activity of Some Acyclic Analogues of the Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotics Tubercidin, Toyocamycin, and Sangivamycin" J. Med. Chem., 32:402-408 (1989).
Puolo, J. S., et al., "Synthesis and Antiviral Activity of Certain 4-and 4,5-Disubstituted 7-[(2-Hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines", J. Med. Chem., 31:2086-2092 (1988).
Vindelov, L. L., "Flow Mirofluorometric Analysis of Nuclear DNA in Cells from Solid Tumors and Cell Suspensions" Virchow's Arch. Cell Pathol. 24:227-242 (1977).
Gadler, H., "Nucleic Acid Hybridization for Measurement of Effects of Antiviral Compounds on Human Cytomegalovirus DNA Replication", Antimicrob. Agents Chemother., 24:370-374 (1983).
Ramasamy, K., et al., "Total Synthesis of 2'-Deoxytoyocamycin, 2'-Deoxysangivamycin and Related 7-.beta.-D-Arabinofuranosyl-Pyrrolo[2,3-d]Pyrimidines via Ring Closure of Pyrrole Precursors Prepared by the Stereospecific Sodium Salt Glycosylation Procedure", Nucleic Acid Research Institute, (Abstract 65).
Tolman, R. L., et al., "Pyrrolopyrimidine Nucleosides III The Total Synthesis of Toyocamycin, Sangivamycin, Tubercidin, and Related Derivatives", J. Am. Chem. Soc. 91:2102-2108 (1969).
Robins, M. J., et al., "A Mild Conversion of Vicinal Diols to Alkenes, Efficient Transformation of Ribonucleosides into 2'-ene and 2',3'-Dideoxynucleosides", Tetrahedron Letters, 25:367-370 (1984).
Jain, T. C. et al., "Reactions of 2-Acyloxyisobutyryl Halides with Nucleosides. III. Reactions of Tubercidin and Formycin", J. Org. Chem., 38:3179-3186 (1973).
DeClercq, E., et al., "Nucleic Acid Related Compounds. 51. Synthesis and Biological Properties of Sugar-Modified Analogues of the Nucleoside Antibiotics Tubercidin, Toyocamycin, Sangivamycin, and Formycin", J. Med. Chem. 30:481-486 (1987).
Hansske, F., et al., "2' and 3'-Ketonucleosides and their Arabino and Xylo Reduction Products", Tetrahedron 40:125-135 (1984).
Smith, C. M., et al. "Inhibitors of Hypoxanthine Metabolism in Ehrlich Ascites Tumor Cells in Virto", Cancer Treatment Reports, 60:1567-1584 (1976).
Maruyama, T., et al., "Pyrrolopyrimidine Nucleosides. 18. Synthesis and Chemotherapeutic Acitivity of 4-Amino-7-(3-deoxy-.beta.-D-ribofuranosyl)pyrrolo-[2,3-d]pyrimidine-5-carb oxamide (3'-Deoxysangivamycin) and 4-Amino-7-(2-deoxy-.beta.-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carbo xamide (2'-Deoxysangivamycin)" J. Med. Chem., 26:25-29 (1983).
Mitsuya, H., et al. "3'-Azido-3'-deoxythymidine (BW A5090): An Antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro", PNAS (USA), 82:7096-7100 (1985).
Mitsuya, H., et al., "Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides", PNAS (USA), 83:1911-1915 (1986).
DeClercq, E., et al., "Antirhinovirus Activity of Purine Nucleoside Analogs", Antimicrob. Agents Chemother., 29:482-484 (1986).
Shipman, C., Jr., "Antiviral Activity of Arabinosyladenine and Arabinosylhypoxanthine in Herpes Simplex Virus-Infected KB Cells; Selective Inhibition of Viral Deoxyribonucleic Acid Synthesis in Synchronized Suspension Cultures", Antimicrob. Agents Chemother., 9:120-127 (1976).
Bergstom, D., et al., "Antiviral Activity of C-5 Substituted Tubercidin Analogues" J. Med. Chem., 27:285-292 (1984).
Turk, S. R., et al., "Pyrrolo[2,3-d]Pyrimidine Nucleosides as Inhibitors of Human Cytomegalovirus", Antimicrob. Agents Chemother., 31:544-550 (1987).
Drach John C.
Townsend Leroy B.
Brown Johnnie R.
Kunz Gary L.
The Regents of the University of Michigan
LandOfFree
Polysubstituted benzimidazole nucleosides as antiviral agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polysubstituted benzimidazole nucleosides as antiviral agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polysubstituted benzimidazole nucleosides as antiviral agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2190992